Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst
May 23, 2017 at 14:09 PM EDT
Barclays initiated coverage of Zymeworks Inc (NYSE: ZYME) with an Overweight rating and price target of $20. The company released ...
